Asset
CASIMERSEN
Sarepta Therapeutics Inc. Common Stock (DE)
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03532542 | phase3 | terminated | 2018-08-02 | 2023-07-26 | Sarepta Therapeutics, Inc. | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 213026 | NDA | SAREPTA THERAPEUTICS INC |
Marketed products (1)
- AMONDYS 45